BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11695549)

  • 1. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
    Robinson DE; MacDonald JS
    Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of human cancer risk: challenges for alternative approaches.
    Omenn GS
    Toxicol Pathol; 2001; 29 Suppl():5-12. PubMed ID: 11695561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panel discussion on the application of alternative models to cancer risk assessment.
    Pettit SD
    Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criteria for the evaluation of studies in transgenic models.
    Popp JA
    Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
    MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
    Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and theEnvironment. Statement on ILSI/HESI research programme on alternative cancer models.
    Blain PG
    Toxicol Pathol; 2003; 31(2):254-7. PubMed ID: 12696588
    [No Abstract]   [Full Text] [Related]  

  • 10. Xpa and Xpa/p53+/- knockout mice: overview of available data.
    van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
    Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expectations for transgenic rodent cancer bioassay models.
    Ashby J
    Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
    Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
    Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tg.AC genetically altered mouse: assay working group overview of available data.
    Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
    Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative models for carcinogenicity testing.
    Cohen SM; Robinson D; MacDonald J
    Toxicol Sci; 2001 Nov; 64(1):14-9. PubMed ID: 11606797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highlights of International meeting on Alternative Methods of Carcinogenicity Testing, Leesburg, VA, November 1-3, 2000, Sponsored by the Health and Environmental Sciences Institute.
    Jollow DJ
    J Agromedicine; 2004; 9(2):427-9. PubMed ID: 19785235
    [No Abstract]   [Full Text] [Related]  

  • 18. A data-based assessment of alternative strategies for identification of potential human cancer hazards.
    Boobis AR; Cohen SM; Doerrer NG; Galloway SM; Haley PJ; Hard GC; Hess FG; Macdonald JS; Thibault S; Wolf DC; Wright J
    Toxicol Pathol; 2009 Oct; 37(6):714-32. PubMed ID: 19700658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
    Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
    Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results.
    Mauthe RJ; Gibson DP; Bunch RT; Custer L
    Toxicol Pathol; 2001; 29 Suppl():138-46. PubMed ID: 11695550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.